Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1714 - Effect of nab-paclitaxel/carboplatin (nab-P/C) induction therapy on quality of life (QoL) of patients with squamous (SCC) non-small cell lung cancer (NSCLC) (ABOUND.sqm)


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Non-Small Cell Lung Cancer


Santiago Ponce Aix


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


S. Ponce Aix1, V. Villaflor2, J. Knoble3, M. Thomas4, J. von Pawel5, S. Bailey6, M.A. Hussein7, M.A. Razaq8, K. Sabbath9, P. Staib10, T. Chen11, N. Trunova11, D.R. Spigel12

Author affiliations

  • 1 Oncology/hematology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 2 Oncology/hematology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago/US
  • 3 Oncology/hematology, Mark H. Zangmeister Center, Columbus/US
  • 4 Oncology/hematology, Thoraxklinik Heidelberg, 69126 - Heidelberg/DE
  • 5 Oncology/hematology, Asklepios-Fachklinikum, 82131 - Gauting/DE
  • 6 Oncology/hematology, Hazard ARH Regional Medical Center Cancer Center, Hazard/US
  • 7 Oncology, Florida Cancer Specialists, Leesburg/US
  • 8 Oncology, Stephenson Cancer Center OU, 73104 - Oklahoma City/US
  • 9 Oncology/hematology, Harold Leever Regional Cancer Center, Waterbury/US
  • 10 Oncology/hematology, St. Antonius Hospital Klinik für Hämatologie/Onkologie, 52249 - Eschweiler/DE
  • 11 Oncology, Celgene Corporation, Summit/US
  • 12 Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203 - Nashville/US


Abstract 1714


Patients with advanced NSCLC experience a high symptom burden; therefore, identifying a treatment that maintains or improves QoL is important. QoL outcomes in patients with SCC NSCLC receiving nab-P/C in the induction part of the ABOUND.sqm study are reported.


Patients with stage IIIB/IV SCC NSCLC and no prior chemotherapy for metastatic disease received 4 cycles of induction therapy with nab-P 100 mg/m2 days 1, 8, and 15 + C area under the curve 6 on day 1 (21-day cycles). Patients not progressing after induction received (2:1) maintenance nab-P 100 mg/m2 days 1 and 8 (21-day cycles) + best supportive care (BSC) or BSC alone until progression/unacceptable toxicity. The primary endpoint is progression-free survival (randomization to maintenance). Patient-reported QoL (exploratory endpoint) was assessed on day 1 of each cycle using the Lung Cancer Symptom Scale (LCSS) and EuroQoL 5 Dimensions-5 Levels (EQ-5D-5L).


In 343 patients receiving treatment in the induction phase were evaluated. Median age was 68 years; 90% were white, 68% male, and 67% had ECOG PS 1. Of 332 patients treated for ≥ 2 cycles, 298 (90%) completed baseline + ≥ 1 postbaseline QoL assessment. During induction, the mean change from baseline in LCSS symptom burden index and total score ranged from 5.5%-7.8% and 5.5%-7.7%, respectively. Clinically meaningful improvements (≥ 10 mm [visual analog scale]) from baseline were observed in composite LCSS pulmonary symptom items of cough, shortness of breath, and hemoptysis in 44% of patients. Each individual dimension of the EQ-5D-5L was maintained/improved from baseline in the majority of patients (82%-91%), and ≥ 32% reported complete resolution at least once during treatment.


QoL was improved/maintained in patients with advanced SCC NSCLC treated with nab-P/C induction therapy. These results continue to support nab-P/C as a treatment option in patients with SCC NSCLC, as was initially demonstrated in a subset analysis of the phase III registration trial. NCT02027428.

Clinical trial identification


Legal entity responsible for the study

Celgene Corporation


Celgene Corporation


V. Villaflor: Research funding from Celgene and Novartis paid directly to University of Chicago. J. Knoble: Consulting or advisory role for Cardinal Health, Speakers\' bureau for Novartis, Alexion and Celgene. M. Thomas: Received honoraria for an advisory/speaker role from: Celgene, Astrazeneca, Roche, BMS, Lilly, Novartis, Boehringer. P. Staib: Honoraria, consulting or advisory role, speaker\'s bureau and research funding: Celgene. T. Chen, N. Trunova: Employment and Stock Ownership: Celgene. D.R. Spigel: Research funding, consulting or advisory role, and travel, accommodations, expenses: Celgene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.